Deal snapshot: Blueprint Medicines Closes Acquisition of Lengo Therapeutics.

MANews-(C)2009-2022

US-based precision therapy company Blueprint Medicines Corp. (NASDAQ: BPMC) has completed the acquisition of Lengo Therapeutics, the company said.

This deal includes Lengo's lead compound LNG-451, a potential best-in-class oral precision therapy in development for the treatment...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT